OSLO, Noorwegen–(BUSINESS WIRE)– NEC OncoImmunity AS (NOI) heeft vandaag een publicatie aangekondigd die een nieuwe benadering beschrijft om nieuwe HLA-allelen te typen en de HLA van tumoren te karakteriseren om gepersonaliseerde kankerimmunotherapie te begeleiden.

De computationele benadering voert HLA-typering uit op basis van sequentiegegevens van de volgende generatie door gebruik te maken van de huidige sterke punten van conventionele HLA-typering en tegelijkertijd de ontdekking van nieuwe HLA-allelen en tumorspecifieke HLA-varianten mogelijk te maken, door gebruik te maken van gepatenteerde mutatie die bio-informatica bij NOI oproept.

NOI werkte samen met Ultimovacs ASA in de studie om de HLA-typeringsbenadering uit het bloed van talrijke donoren te valideren met behulp van diep gerichte HLA-sequencing. De validatie bevestigde bijna 100% van het succes van HLA-typering in het 1e en 2e resolutieveld.

NEC OncoImmunity Publishes a Unique HLA Typing Technology That Discovers New HLA Alleles, and Tumor Specific HLA Alleles

OSLO, Norway–(BUSINESS WIRE)– NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized cancer immunotherapy.

The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI.

NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing approach from the blood of numerous donors using deep targeted HLA sequencing. The validation confirmed almost 100% of HLA typing success at the 1^st and 2^nd fields of resolution.

The approach was published in the peer review journal HLA where the first author Anzar and her colleagues also demonstrated how the approach led to the discovery of a new officially named HLA allele, from standard sequencing data routinely used in the design of personalized cancer vaccines.

“This approach is an important development in the field of precision immunotherapy. It will help the HLA typing community to fill gaps in the global human HLA libraries, and help identify novel HLA variants in disease association studies in addition to improving the accuracy of HLA-typing for organ transplantation and vaccine design. We will now use this unique addition to our bioinformatics toolbox to further characterize the relationship between variation in HLA alleles and response to cancer immunotherapy.” Said, Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity.

References

Title: Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants

Authors: Irantzu Anzar, Angelina Sverchkova, Pubudu Samarakoon, Espen Basmo Ellingsen, Gustav Gaudernack, Richard Stratford and Trevor Clancy

URL: https://onlinelibrary.wiley.com/doi/10.1111/tan.14562

About NEC OncoImmunity AS

NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. The AI technology can be used to identify optimal antigen/epitope targets for infectious disease vaccines, truly personalized cancer vaccines & Tcell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at http://www.oncoimmunity.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220216006099/en/

Contacts

Trevor Clancy

trevor@oncoimmunity.com